Soliqua Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Regulatory Classification Presentation/Packing Brand Resources

Full Prescribing Info

Adverse Reactions

The most frequently reported adverse reactions during treatment with Insulin Glargine + Lixisenatide (Soliqua) were hypoglycaemia and gastrointestinal adverse reactions.
The following related adverse reactions from clinical investigations are listed below by system organ class and in order of decreasing frequency (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000).
Very common: Metabolism and nutrition disorders: Hypoglycaemia.
Common: Nervous system disorders: Dizziness.
Gastrointestinal disorders: Nausea, Diarrhoea and Vomiting.
Uncommon: Infections and infestations: Nasopharyngitis and Upper respiratory tract infection.
Immune system disorders: Urticaria.
Nervous system disorders: Headache.
Gastrointestinal disorders: Dyspepsia and Abdominal pain.
General disorders and administration site conditions: Fatigue and Injection site reactions.

View ADR Monitoring Form

insulin glargine + lixisenatide

Manufacturer:

sanofi-aventis

Distributor:

sanofi-aventis